A strategic collaboration was announced at the Association for Molecular Pathology (AMP) Annual Meeting between Complete Genomics a leader in genomic sequencing, and SOPHiA GENETICSa global innovator in AI-driven precision medicine. This partnership is focused on co-marketing and launching the MSK-ACCESS® and MSK-IMPACT® oncology assays, powered with SOPHiA DDM™, on Complete Genomics’ newly introduced DNBSEQ-T1+ sequencing platform.

This partnership aims to significantly broaden global access to precision oncology testing by providing a best-in-class, integrated, sample-to-report workflow for both liquid biopsy and solid tumor applications to laboratories.

The collaboration combines the rigorously validated Memorial Sloan Kettering Cancer Center (MSK) assays with SOPHiA GENETICS’ robust, AI-powered SOPHiA DDM™ analytics platform and Complete Genomics’ DNBSEQ-T1+ platform, marking a key expansion into the precision oncology research market.

Complete Genomics highlighted that pairing the solutions creates a powerful, accessible system enabling decentralized labs to deliver faster, more accurate, and more affordable genomic insights to clinicians and researchers. The DNBSEQ-T1+, leveraging proprietary DNBSEQ technology, offers Q40-level accuracy and flexible throughput ranging from 500 million to 2 billion reads per flow cell, each running independently with a 24-hour paired-end 150bp run time, and capable of processing up to 60 tumor-normal tissue pairs or 16 liquid biopsy pairs per flow cell. Joint evaluation of the integrated system demonstrated highly concordant variant calls and allele frequencies when compared to equivalent sequencing systems, while achieving crucial benefits such as lower background noise and reduced turnaround time. This new high-performance, cost-efficient offering provides clinical laboratories, cancer centers, and drug developers a streamlined path to implement comprehensive genomic profiling for oncology research.